Investigational drug · Phase 2
AZD7789
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 9, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "AZD7789"
First trial start
2021
Sep 28, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD7789", any sponsor or status.
Conditions studied
As listed on its trial records.
- Carcinoma, Non-Small-Cell Lung
- Gastric Cancer
- Gastroesophageal Junction Cancer
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD7789" as an intervention, largest first.
- Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04612751 · 155 participants · Start Feb 2, 2021 · Primary completion May 4, 2026
Drug: Datopotamab deruxtecan; Durvalumab and 4 more · For: Advanced or Metastatic NSCLC
Sites: La Jolla, California; Santa Ana, California; St Louis, Missouri · 42 sites in all
- A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT04931654 · 136 participants · Start Sep 28, 2021 · Primary completion Dec 4, 2024
Drug: AZD7789 · For: Carcinoma, Non-Small-Cell Lung; Gastric Cancer; Gastroesophageal Junction Cancer
Sites: Atlanta, Georgia; Fort Wayne, Indiana; New York, New York · 21 sites in all
AstraZenecaAstraZeneca (AZN)
NCT05216835 · 45 participants · Start Mar 18, 2022 · Primary completion Aug 30, 2024
Drug: Sabestomig (AZD7789) · For: Relapsed or Refractory Classical Hodgkin Lymphoma
Sites: Duarte, California; Miami, Florida; Rochester, Minnesota · 14 sites in all
Presage BiosciencesIndustry
NCT06366451 · 17 participants · Start May 22, 2024 · Primary completion Mar 25, 2026
Drug: Rilvegostomig; Volrustomig and 3 more · For: Head and Neck Squamous Cell Carcinoma
Sites: Sacramento, California; The Bronx, New York; Chapel Hill, North Carolina · 7 sites in all
- Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer TherapiesActive, not recruiting
Presage BiosciencesIndustry
NCT04541108 · 15 participants (planned) · Start Jul 26, 2021 · Primary completion Dec 2031
Drug: Rilvegostomig; Volrustomig and 3 more · For: Solid Tumor
Sites: Shreveport, Louisiana; The Bronx, New York; Chapel Hill, North Carolina · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Carcinoma, Non-Small-Cell Lung
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- OleclumabMEDI9447Phase 37 trials
AstraZeneca · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Metastatic Microsatellite-stable Colorectal Cancer
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- NavlimetostatBMS-986504, MRTX1719Phase 34 trials
Bristol Myers Squibb · Pancreatic Ductal Adenocarcinoma, Metastatic Non-small Cell Lung Cancer With MTAP Deletion, Solid Tumors
- Sigvotatug VedotinSGN-B6A, PF-08046047Phase 33 trials
Pfizer · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.